← Evidence map

ArticleHepatology (Baltimore, Md.)2015

Erlotinib might be a double-edged sword in HCC.

Jin-Zhong Dong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2015

2016

2017

2018

this papercites it

Erlotinib might be a double-edged sword in HCC. | OpenQuestion